恆大健康(00708.HK)續漲近35% 曾逼近52周高
繼美國多州新冠肺炎疫情反彈後,日本東京昨天確診病例也突破40宗,北京更爆發群組感染,昨天本土新增病例急增至36宗,上周尾斥近3.8億美元收購瑞典附屬電動車商NEVS餘下17.6%股權至全資擁有的恆大健康(00708.HK)承過去兩天逆漲勢,今天股價突破牛熊線(7.38元)後,有買盤跟進,升幅曾擴至38%高見9.85元,暫受制去年7月初盤中所創52周高位10.5元,現造9.6元,急漲近35%,成交急增至1,875萬股,創逾年半高,涉資近1.73億元。
恆大健康主要從事互聯網+社區健康管理、國際醫院、養老及康復產業等,同時也從事投資高科技新能源汽車製造。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.